L3VLUP
ProSign in

FATE · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

FATEAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • FATE
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterFATEAMGN
Q3 20208 holders, $446m16 holders, $16.3bn
Q4 202011 holders, $2.0bn19 holders, $14.0bn
Q1 202110 holders, $2.1bn16 holders, $14.5bn
Q2 202111 holders, $2.1bn23 holders, $13.8bn
Q3 20219 holders, $1.3bn24 holders, $11.6bn
Q4 20217 holders, $971m21 holders, $10.4bn
Q1 20227 holders, $677m23 holders, $9.9bn
Q2 20226 holders, $520m28 holders, $9.7bn
Q3 20227 holders, $494m21 holders, $7.9bn
Q4 20225 holders, $116m24 holders, $9.3bn
Q1 20232 holders, $483k22 holders, $8.4bn
Q2 20232 holders, $4.5m26 holders, $7.4bn
Q3 20233 holders, $4.9m26 holders, $8.7bn
Q4 20232 holders, $10.0m24 holders, $8.4bn
Q1 20245 holders, $51m25 holders, $6.7bn
Q2 20243 holders, $10m20 holders, $8.0bn
Q3 20243 holders, $17m21 holders, $8.8bn
Q4 2024none listed holders, n.a.20 holders, $8.2bn
Q1 20251 holders, $6.2m25 holders, $12.0bn
Q2 2025none listed holders, n.a.20 holders, $10.2bn
Q3 2025none listed holders, n.a.17 holders, $10.4bn
Q4 2025none listed holders, n.a.19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 2026none listed holders, n.a.23 holders, $24.9bn
FATE

Fate Therapeutics Inc

Holders
1
Reported value
$6.2m
Buyers
1
Sellers
0

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
25
Reported value
$12.0bn
Buyers
10
Sellers
16

Breadth -6 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only FATE (1)

Schonfeld Strategic Advisors LLC

Only AMGN (25)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →